Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18701894 | 0.93 | CYP3A4 (0.37) | CYP3A4EPHX2PDK2ALDH1A1HTT | |
| SCHEMBL18212196 | 0.89 | CYP3A4 (0.40) | CYP3A4EPHX2PDK2ALDH1A1HTT | |
| SCHEMBL16886332 | 0.81 | EPHX2 (0.40) | CYP3A4EPHX2PDK2ALDH1A1HTT | |
| SCHEMBL20682387 | 0.80 | PDK2 (0.36) | CYP3A4EPHX2PDK2MEN1KMT2A | |
| SCHEMBL16888554 | 0.80 | CYP1A2 (0.41) | CYP3A4EPHX2PDK2ALDH1A1VNN1 | |
| SCHEMBL27896663 | 0.79 | RORC (0.41) | ALDH1A1HTTVNN1MEN1KMT2A | |
| SCHEMBL3869090 | 0.78 | VNN1 (0.38) | ALDH1A1HTTVNN1TRPA1 | |
| SCHEMBL13223563 | 0.78 | CYP3A4 (0.43) | CYP3A4EPHX2PDK2ALDH1A1HTT | |
| SCHEMBL1104454 | 0.78 | CYP3A4 (0.40) | CYP3A4EPHX2PDK2ALDH1A1HTT | |
| SCHEMBL18701893 | 0.77 | CYP3A4 (0.38) | CYP3A4EPHX2PDK2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | CYP3A4 436/4885EPHX2 1398/4885PDK2 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.